AAREYDRUGS

Aarey Drugs & Pharmaceuticals Share Price

₹58.96 +0.99 (1.71%)

21 Dec, 2024 18:29

SIP TrendupStart SIP in AAREYDRUGS

Start SIP

Performance

  • Low
  • ₹59
  • High
  • ₹59
  • 52 Week Low
  • ₹37
  • 52 Week High
  • ₹75
  • Open Price₹0
  • Previous Close₹58
  • Volume9,542

Investment Returns

  • Over 1 Month + 8.12%
  • Over 3 Month -12.39%
  • Over 6 Month + 29.58%
  • Over 1 Year + 30.73%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarey Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Aarey Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 167
  • P/B Ratio
  • 1.3
  • Average True Range
  • 1.93
  • EPS
  • 2.47
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.32
  • RSI
  • 46.79
  • MFI
  • 40.28

Aarey Drugs & Pharmaceuticals Financials

Aarey Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹58.96
+ 0.99 (1.71%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹59.53
  • 50 Day
  • ₹60.43
  • 100 Day
  • ₹59.73
  • 200 Day
  • ₹56.47

Resistance and Support

59.01 Pivot Speed
  • R3 59.23
  • R2 59.17
  • R1 59.07
  • S1 58.91
  • S2 58.85
  • S3 58.75

What's your outlook on Aarey Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarey Drugs & Pharms. has an operating revenue of Rs. 518.89 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 22% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 50 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarey Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-12-04 To consider Fund Raising
2024-11-29 Preferential issue of shares Inter alia: a) To consider a proposal for issuance of equity shares by way of a preferential allotment.
2024-11-14 Quarterly Results
2024-10-01 Others
2024-08-14 Quarterly Results

Aarey Drugs & Pharmaceuticals F&O

Aarey Drugs & Pharmaceuticals Shareholding Pattern

45.44%
2.75%
47.57%
4.24%

About Aarey Drugs & Pharmaceuticals

  • NSE Symbol
  • AAREYDRUGS
  • BSE Symbol
  • 524412
  • Chairman & Managing Director
  • Mr. Mihir R Ghatalia
  • ISIN
  • INE198H01019

Similar Stocks to Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals FAQs

Aarey Drugs & Pharmaceuticals share price is ₹58 As on 21 December, 2024 | 18:15

The Market Cap of Aarey Drugs & Pharmaceuticals is ₹167.2 Cr As on 21 December, 2024 | 18:15

The P/E ratio of Aarey Drugs & Pharmaceuticals is 27.8 As on 21 December, 2024 | 18:15

The PB ratio of Aarey Drugs & Pharmaceuticals is 1.3 As on 21 December, 2024 | 18:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23